Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Yuan Tian Qun Zhao Yong Li Liqiao Fan Zhidong Zhang Xuefeng Zhao Bibo Tan Dong Wang Peigang Yang

Published in: Gastroenterology research and practice (2021)

Neoadjuvant DOX is an effective and feasible regimen and might represent an option for young and middle-aged patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma.

Keyphrases

locally advanced
neoadjuvant chemotherapy
middle aged
rectal cancer
squamous cell carcinoma
radiation therapy
phase ii study
sentinel lymph node
early stage
lymph node
study protocol
double blind